Glenmark Pharmaceuticals Inc., USA has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux-E Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIA sales data for the 12 month period ending September 2018, the Olux-E Foam, 0.05% market achieved annual sales of around $13.2 million.
The company’s current portfolio consists of 144 products authorized for distribution in the US marketplace and 55 ANDAs pending approval with the USFDA. In addition to these, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).